双胎妊娠10-14周母血游离DNA筛查21/18/13三体的队列研究与Meta分析
本研究扩展了FMF双胎妊娠10-14周cfDNA筛查21/18/13三体的前瞻性数据,并系统检索文献进行Meta分析。FMF队列1442例双胎中1367例获得结果,1272例纳入分析;cfDNA对21三体检出率95.0%,18三体90.0%,13三体50.0%,假阳性率低。Meta分析合并后21三体DR 99.0%(95%CI 92.0-99.9%),18三体92.8%(95%CI 77.6-98.0%),13三体94.7%(95%CI 9.14-99.97%)。
要点
- 双胎妊娠cfDNA对21三体检出率高(合并DR 99.0%),但低于单胎,假阳性率低(0.02%)。
- 18三体和13三体病例数少,预测性能评估不准确,13三体置信区间极宽。
- 双胎妊娠筛查咨询需告知cfDNA对21三体高效,但对18/13三体证据有限。
核心结论
- 双胎妊娠cfDNA筛查21三体的报告检出率高但低于单胎,假阳性率同样低;18和13三体病例数过少无法准确评估预测性能。
研究设计与样本
- FMF前瞻性队列:双胎妊娠10+0至14+1周行Harmony®产前检测筛查21/18/13三体。
- 文献检索MEDLINE、EMBASE、CENTRAL、ClinicalTrials.gov和WHO ICTRP,纳入妊娠结局随访率≥85%的同行评议研究。
- Meta分析合并FMF数据与12项文献研究,PROSPERO注册。
诊断标准与关键数值
- FMF队列1272例中21三体20例、18三体10例、13三体2例;cfDNA正确分类分别为19/20(95.0%)、9/10(90.0%)、1/2(50.0%),非三体1240例中1235例正确(99.6%)。
- 合并分析21三体137例与非三体7507例,加权DR 99.0%(95%CI 92.0-99.9%),FPR 0.02%(95%CI 0.001-0.43%)。
- 合并分析18三体50例与非三体6840例,加权DR 92.8%(95%CI 77.6-98.0%),FPR 0.01%(95%CI 0.00-0.44%)。
- 合并分析13三体11例与非三体6290例,加权DR 94.7%(95%CI 9.14-99.97%),FPR 0.10%(95%CI 0.03-0.39%)。
临床应用与阅片要点
- 双胎妊娠早孕期筛查可向孕妇说明cfDNA对21三体高效且假阳性率低,但检出率低于单胎。
- 对18和13三体,cfDNA阴性不能完全排除,因证据病例数少,需结合超声或其他筛查。
- 解读双胎cfDNA结果时注意13三体置信区间极宽,避免过度依赖其阴性预测值。
局限性
- 18三体和13三体病例数少,无法准确评估cfDNA预测性能。
- FMF队列中95例因无核型或失访被排除,可能引入偏倚。
- 文献异质性及不同检测平台可能影响合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To expand the limited knowledge on cell-free DNA (cfDNA) analysis of maternal blood for trisomies 21, 18 and 13 in twin pregnancy by updating the data from The Fetal Medicine Foundation (FMF) on prospective first-trimester screening and those identified in a systematic review of the literature.
METHODS: The FMF data were derived from prospective screening for trisomies 21, 18 and 13 in twin pregnancies at 10 + 0 to 14 + 1 weeks' gestation using the Harmony® prenatal test. A search of MEDLINE, EMBASE, CENTRAL (The Cochrane Library), ClinicalTrials.gov and the International Clinical Trials Registry Platform (World Health Organization) was carried out to identify all peer-reviewed publications on clinical validation or implementation of maternal cfDNA testing for trisomies 21, 18 and 13 in twin pregnancy, irrespective of gestational age at testing, in which data on pregnancy outcome were provided for at least 85% of the study population. Meta-analysis was performed using the FMF data and data from the studies identified by the literature search. This review was registered in the PROSPERO international database for systematic reviews RESULTS: In the FMF study, cfDNA testing was carried out in 1442 twin pregnancies and a result was obtained, after first or second sampling, in 1367 (94.8%) cases. In 93.1% (1272/1367) of cases, there was prenatal or postnatal karyotyping or birth of phenotypically normal babies; 95 cases were excluded from further analysis either because the pregnancy ended in termination, miscarriage or stillbirth with no known karyotype (n = 56) or there was loss to follow-up (n = 39). In the 1272 pregnancies included in the study, there were 20 cases with trisomy 21, 10 with trisomy 18, two with trisomy 13 and 1240 without trisomy 21, 18 or 13. The cfDNA test classified correctly 19 (95.0%) of the 20 cases of trisomy 21, nine (90.0%) of the 10 cases of trisomy 18, one (50.0%) of the two cases of trisomy 13 and 1235 (99.6%) of the 1240 cases without any of the three trisomies. The literature search identified 12 relevant studies, excluding our papers because their data are included in the current study. In the combined populations of our study and the 12 studies identified by the literature search, there were 137 trisomy-21 and 7507 non-trisomy-21 twin pregnancies; the pooled weighted detection rate (DR) and false-positive rate (FPR) were 99.0% (95% CI, 92.0-99.9%) and 0.02% (95% CI, 0.001-0.43%), respectively. In the combined total of 50 cases of trisomy 18 and 6840 non-trisomy-18 pregnancies, the pooled weighted DR and FPR were 92.8% (95% CI, 77.6-98.0%) and 0.01% (95% CI, 0.00-0.44%), respectively. In the combined total of 11 cases of trisomy 13 and 6290 non-trisomy-13 pregnancies, the pooled weighted DR and FPR were 94.7% (95% CI, 9.14-99.97%) and 0.10% (95% CI, 0.03-0.39%), respectively.
CONCLUSIONS: In twin pregnancy, the reported DR of trisomy 21 by cfDNA testing is high, but lower than that in singleton pregnancy, whereas the FPR appears to be equally low. The number of cases of trisomy 18 and more so trisomy 13 was too small for accurate assessment of the predictive performance of the cfDNA test. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Judah H, Gil MM, Syngelaki A, et al. Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis. Ultrasound Obstet Gynecol. 2021. PMID: 33838069. doi:10.1002/uog.23648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。